Clinical Trial Detail

NCT ID NCT01841463
Title Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Recruitment Suspended
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Piramal Enterprises Limited
Indications

melanoma

Therapies

Vemurafenib + Voruciclib

Age Groups: adult senior

Additional content available in CKB BOOST